URBANDALE, Iowa — June 6, 2017 — New cleanroom at Iowa location adds capability to compound intravenous nutrition treatments.

Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy Inc. (NYSE: DPLO), has added a sterile compounding environment to its Iowa location.

The Iowa facility in Urbandale now features an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. A cleanroom is a controlled environment with a low level of pollutants.

“Our new cleanroom will allow us to serve more IV nutrition consumers and better serve our Iowa patients,” said Phil Rielly, Diplomat vice president and president of Diplomat Specialty Infusion Group. “Our goal is to enhance consumers’ quality of life through clinical excellence; customized care; and consumer support and advocacy.”

Diplomat Specialty Infusion Group is a home infusion pharmacy providing therapies for consumers across the United States. ThriveRx, its nutrition division, focuses on home parenteral and enteral nutrition consumers. ThriveRx consumers receive customized Diplomat therapies and access to nutrition experts who provide:

  • Home parenteral and enteral nutrition support
  • Programs designed to help consumers achieve their nutrition goals
  • Education, tools, and guidance to help them thrive

To learn more about Diplomat’s specialty infusion services, visit diplomat.is/specialtyinfusion.

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

###

CONTACT:
Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Deb Pfister, ThriveRx
978.501.0801 | dpfister@diplomat.is

 

Twitter